Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00103974
What this trial is testing

Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Bayhill Therapeutics 30
Testing effectiveness (Phase 2)Study completedNCT00912860
What this trial is testing

Immunogenicity and Safety Study of Serum-Free Avonex

Who this might be right for
Multiple Sclerosis
Biogen 155
Testing effectiveness (Phase 2)Study completedNCT02212886
What this trial is testing

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

Who this might be right for
Multiple Sclerosis
Mapi Pharma Ltd. 25
Not applicableStudy completedNCT05697523
What this trial is testing

Multiple Sclerosis and Respiratory and Functional Capacity

Who this might be right for
Multiple Sclerosis
Nigde Omer Halisdemir University 80
Large-scale testing (Phase 3)WithdrawnNCT01337427
What this trial is testing

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Johns Hopkins University
Testing effectiveness (Phase 2)Study completedNCT05131828
What this trial is testing

CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy

Who this might be right for
Multiple Sclerosis
Cambridge University Hospitals NHS Foundation Trust 70
Post-approval studies (Phase 4)WithdrawnNCT01621269
What this trial is testing

ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT01808885
What this trial is testing

Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Hoffmann-La Roche 44
Not applicableUnknownNCT05277740
What this trial is testing

Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis

Who this might be right for
Clinically Isolated SyndromeRelapsing Remitting Multiple Sclerosis
McGill University 120
Not applicableStudy completedNCT04221191
What this trial is testing

Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 353
Not applicableUnknownNCT06325358
What this trial is testing

The EXPOSITION Study

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingEnvironmental ExposureLifestyle Factors
University of Pavia 200
Early research (Phase 1)Study completedNCT00837785
What this trial is testing

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 48
Testing effectiveness (Phase 2)UnknownNCT04711148
What this trial is testing

Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Beijing InnoCare Pharma Tech Co., Ltd. 160
Not applicableStudy completedNCT00206635
What this trial is testing

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Bayer 432
Post-approval studies (Phase 4)Study completedNCT00492765
What this trial is testing

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Biogen 380
Post-approval studies (Phase 4)Study completedNCT00176592
What this trial is testing

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

Who this might be right for
Multiple Sclerosis
University of Medicine and Dentistry of New Jersey 75
Not applicableStudy completedNCT07273604
What this trial is testing

Psychological Interventions for Multiple Sclerosis: Effects on Anxiety, Depression, and Cognition.

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remittingAnxietyDepression+3 more
Moisés Bermúdez Hernández 140
Early research (Phase 1)Study completedNCT01257958
What this trial is testing

Vitamin D Pilot Study in Patients With Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Wisconsin, Madison
Large-scale testing (Phase 3)Ended earlyNCT00297232
What this trial is testing

Natalizumab (Tysabri) Re-Initiation of Dosing

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 1,094
Post-approval studies (Phase 4)Study completedNCT01144052
What this trial is testing

Natalizumab De-escalation With Interferon Beta-1b

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Claudio Gobbi 19
Next Page